dexcom, inc. (nasdaq: dxcm) announced the appointment of renée galá to its board of directors, effective march 6, 2025. galá, currently the president and coo of jazz pharmaceuticals, brings extensive experience in finance, strategic leadership, and operations in the life sciences sector.

before joining jazz pharmaceuticals, galá served as cfo at grail, inc. and theravance biopharma, inc. she also held various finance and business development roles at eli lilly and company.

dexcom’s chairman and ceo, kevin sayer, stated that galá’s expertise in global operations and finance will support dexcom’s mission to enhance metabolic health and drive shareholder value.